What antithyroid medication regimen should be used during pregnancy, including drug choice by trimester, dosing, monitoring, and management of adverse effects?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 27, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Antithyroid Drugs in Pregnancy

Use propylthiouracil (PTU) during the first trimester, then switch to methimazole for the second and third trimesters to minimize both teratogenic risk and maternal hepatotoxicity. 1, 2

Drug Selection by Trimester

First Trimester (Weeks 0-13)

  • PTU is the drug of choice because methimazole/carbimazole causes specific congenital malformations including choanal atresia, esophageal atresia, and aplasia cutis 1
  • Starting dose: 50-150 mg daily 3
  • For women already on methimazole who become pregnant: obtain pregnancy testing at earliest suspicion and switch to PTU immediately 1

Second and Third Trimesters (Weeks 14-40)

  • Switch from PTU to methimazole at the beginning of the second trimester 1, 2
  • This switch reduces risk of PTU-induced hepatotoxicity, which can be catastrophic and potentially fatal 1, 4
  • Dose conversion: 300 mg PTU ≈ 10-15 mg methimazole (20-30:1 potency ratio) 1
  • Starting methimazole dose if initiating in 2nd/3rd trimester: 5-10 mg daily 3

Alternative approach: If hyperthyroidism improves significantly and dose reduction/cessation is possible, continuing PTU throughout pregnancy may be considered to avoid destabilization from switching 3. However, this requires monitoring hepatic enzymes every 4 weeks alongside thyroid function, though no prospective data prove this prevents fulminant hepatotoxicity 1.

Dosing Strategy

Use the lowest possible dose to maintain maternal thyroid hormones slightly above normal range 1:

  • Target free T4: at or slightly above upper limit of non-pregnant reference range
  • Target total T4: upper one-third of pregnancy-specific range (1.5× non-pregnant range)
  • TSH may remain suppressed throughout pregnancy and should not be the sole guide 1
  • Never use block-replacement therapy (antithyroid drug + levothyroxine) in pregnancy—risk of fetal hypothyroidism 1

Monitoring Protocol

Monthly thyroid function assessment is mandatory 1:

  • Check thyroid function 2 weeks after treatment initiation
  • Then every 2-4 weeks throughout pregnancy or while on antithyroid drugs 3
  • When switching drugs, intensify monitoring due to pharmacokinetic differences and dose equivalency uncertainty 1, 3
  • Free T4 correlates best with fetal outcomes 1

TRAb (TSH Receptor Antibody) Monitoring

  • Measure at diagnosis if Graves' disease confirmed or suspected 1
  • Repeat at 22-26 weeks gestation if initially elevated 1
  • For women previously treated with radioactive iodine or thyroidectomy: measure at 22-26 weeks or initially in first trimester then again at 22-26 weeks if elevated 1
  • Results guide neonatal monitoring decisions 1

Management of Adverse Effects

PTU-Associated Hepatotoxicity

  • Rare but potentially fatal, including risk of liver failure requiring transplantation 1, 4
  • Consider hepatic enzyme monitoring every 4 weeks if continuing PTU beyond first trimester 1
  • Stop immediately if liver enzymes become significantly abnormal 3

Methimazole-Associated Birth Defects

The evidence shows increased risk but smaller absolute numbers 5:

  • Excess risk of any birth defects: 17.8 per 1000 pregnancies
  • Excess risk of major birth defects: 2.3 per 1000 pregnancies
  • Pattern includes choanal/esophageal atresia, aplasia cutis, facial/cardiac/GI/skin anomalies 6

PTU-Associated Birth Defects

  • Lower frequency and severity compared to methimazole 3, 5
  • Excess risk of any birth defects: 10.2 per 1000 pregnancies
  • Excess risk of major birth defects: 1.3 per 1000 pregnancies

Critical Pitfalls to Avoid

  1. Do not treat transient hCG-mediated TSH suppression in early pregnancy—this is physiologic and does not require antithyroid drugs 1

  2. Avoid switching drugs carelessly—the transition can destabilize thyroid control due to different pharmacokinetics 1. Requires closer monitoring.

  3. Do not aim for normal TSH—TSH may remain suppressed even with adequate treatment; use free T4 as primary guide 1

  4. Avoid fetal hypothyroidism—antithyroid drugs cross the placenta while T4/T3 cross minimally. Keep doses minimal once fetal thyroid functions (second/third trimesters) 1

  5. Untreated hyperthyroidism carries its own risks—excess risk of birth defects is 9.6 per 1000, similar to PTU 5. Serious maternal/fetal complications including miscarriage and stillbirth occur with uncontrolled disease 7, 8.

Surgical Considerations

Thyroidectomy is reserved for severe antithyroid drug allergy or poor disease control 3, 2. If necessary, perform during the second trimester 1.

Postpartum Management

  • Distinguish postpartum thyroiditis from postpartum Graves' disease with selective diagnostic studies 1
  • For symptomatic postpartum thyrotoxicosis: use beta-blockers judiciously 1
  • Methimazole is preferred during breastfeeding over PTU due to hepatotoxicity risk to mother or infant 1
  • Both drugs appear in breast milk in small concentrations with normal infant thyroid function and development documented 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.